BioMarin Attains 52-Week High


Shares of BioMarin Pharmaceutical Inc. (BMRN) ended the trading session on Apr 10, 2013 by reaching its 52-week high of $64.27. The company is expected to report its first quarter 2013 results on Apr 25.

With more than 23% of year-to-date return and a long-term expected earnings growth rate of 36.0%, this biopharmaceutical company seems to be an attractive pick for long-term investors. Average volume of shares traded over the last three months stands at approximately 1,189K. The company had a market capitalization of $8.1 billion on Apr 10.

On Feb 21, 2013, BioMarin reported higher-than-expected revenues of $131.9 million on the back of higher product sales for the final quarter of 2012. BioMarin expects to generate total revenues in the range of $530–$555 million in 2013. The company generated revenues of $500.7 million in 2012.

BioMarin’s current approved products include Naglazyme (MPS-VI), Aldurazyme (enzyme replacement therapy), Kuvan (phenylketonuria) and Firdapse (:LEMS). Naglazyme, the company’s highest contributor of revenues, is expected to generate around $265–$285 million as product sales in 2013.

Multiple Pipeline-Related Events Lined Up

Moreover, BioMarin has a robust pipeline with several data readouts expected this year. The company recently submitted a submitted a Biologics License Application (:BLA) to the US Food and Drug Administration (:FDA) for its lead candidate, Vimizim (BMN-110, elosulfase alfa).

The candidate is developed for the treatment of patients suffering from mucopolysaccharidosis Type IVA (MPS IVA) or morquio A syndrome. The company expects the candidate to be approved by the end of 2013. We believe investor focus to remain on the regulatory status of Vimizim.

BioMarin’s pipeline includes PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (:PKU), BMN-673 - a poly polymerase inhibitor and BMN-701 for Pompe’s disease among others. On approval these candidates will also drive growth at BioMarin.

Premium Valuation Justified

On a price-to-sales basis BioMarin is trading at 16.0x, reflecting a huge premium of 363.8% compared with the peer group average of 3.45x. On a price-to-book basis, the stock is also trading at a premium to the peer group average. Given the company’s strong fundamentals, the premium valuation is justified.

Other Stocks to Consider

BioMarin, a biopharma company, currently carries a Zacks Rank #3 (Hold). However other biopharma stocks such as UCB (UCBJF), Athersys Inc. (ATHX) and Celgene Corporation (CELG) currently look more attractive and are worth considering. While UCB and Athersys carry a Zacks Rank #1 (Strong Buy), Celgene carries a Zacks Rank #2 (Buy).

Read the Full Research Report on BMRN

Read the Full Research Report on UCBJF

Read the Full Research Report on CELG

Read the Full Research Report on ATHX

Zacks Investment Research

More From
View Comments (0)